0001209191-19-002955.txt : 20190108 0001209191-19-002955.hdr.sgml : 20190108 20190108211612 ACCESSION NUMBER: 0001209191-19-002955 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190104 FILED AS OF DATE: 20190108 DATE AS OF CHANGE: 20190108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Robert E CENTRAL INDEX KEY: 0001291959 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 19517183 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BOULEVARD CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-04 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001291959 Davis Robert E C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 SVP, Chief Scientific Officer Common Stock 2019-01-04 4 S 0 6862 11.33 D 46691 D Common Stock 2019-01-04 4 S 0 2702 11.80 D 43989 D Stock Option (right to buy) 12.73 2019-01-08 4 A 0 75554 0.00 A 2029-01-07 Common Stock 75554 75554 D Restricted Stock Units 2019-01-08 4 A 0 54988 0.00 A Common Stock 54988 54988 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2018. The proceeds from these sales will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.78 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. On January 8, 2019, the reporting person was granted options to purchase 75,554 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock. On January 8, 2019, the reporting person was granted 54,988 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Lawrence J. Hineline, Attorney-in-fact 2019-01-08